Idronoxil as an Anticancer Agent: Activity and Mechanisms

(E-pub Ahead of Print)

Author(s): Kate Porter*, W. Douglas Fairlie, Olivier Laczka, Frederic Delebecque, John Wilkinson.

Journal Name: Current Cancer Drug Targets

Become EABM
Become Reviewer


Idronoxil has been the subject of more than 50 peer reviewed publications over the last two decades. This isoflavone is an intriguing regulator of multiple signal transduction pathways, capable of causing a range of biological effects, including cell cycle arrest, apoptosis, an ability to stimulate the immune system, and inhibition of angiogenesis. These multifaceted actions suggest that idronoxil has the potential to synergize with, or complement, a wide range of cancer therapies. Whilst clinically tested in the past, idronoxil’s journey was discontinued as a result of its low bioavailability in humans when administered either intravenously or orally, though strategies to overcome this issue are currently being explored. Here, we summarize the current literature regarding the key cellular targets of idronoxil and the mechanisms by which idronoxil exerts its anticancer effects, laying a new foundation toward giving this unique molecule a second chance at contributing to the future of cancer treatment.

Keywords: Idronoxil, Phenoxodiol, Immunomodulation, Oncology, Apoptosis, Cancer therapy, Signal transduction modulators

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1568009620666200102122830
Price: $95

Article Metrics

PDF: 5